TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01074099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMAC
Description: Injection of BMAC into ischemic myocardium during CABG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG only
Description: Control subjects will undergo CABG surgery without BMAC injection
Study: NCT03669848

Intervention type: OTHER
Intervention: Pulse CO-oximetry
Description: Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
Study: NCT01535404

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing
Description: Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing
Description: Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
Study: NCT01012999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil
Description: Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
Study: NCT01797822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01089972

Intervention type: DEVICE
Intervention: 22 gauge catheter
Description: radial artery cannulation using 22 gauge catheter

Intervention type: DEVICE
Intervention: 20 gauge catheter
Description: radial artery cannulation using 20 gauge catheter
Study: NCT03137134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor, esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor, esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor, esomeprazole
Study: NCT03771482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiztime modules
Description: Text Messaging or Email system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiztime modules
Description: Text Messaging or Email system
Study: NCT01741753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Orally, every morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally, 1000 mg, every morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally, 5 mg, every morning
Study: NCT02509533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.®
Description: Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dressing
Description: Patients received usual dressing method (compresses) after a transplants of leg ulcers
Study: NCT01797822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tear
Study: NCT03058679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
Study: NCT02136277

Intervention type: DRUG
Intervention: Hartmann's solution
Description: Administered in 250ml boluses, until cardiac output has been optimised.
Study: NCT03155607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Patient will utilize a virtual reality device during wound care.
Study: NCT00982358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01737034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention by varying GI diets
Description: The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention by varying GI diets
Description: The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention by varying GI diets
Description: The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention by varying GI diets
Description: The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
Study: NCT01113541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone HCL (oral)
Description: Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
Study: NCT04158453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUT00201
Description: Oral dose of AUT00201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo
Study: NCT01798238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
Study: NCT02547025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole+3 antibiotics
Description: (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole+bismuth+2 antibiotics
Description: (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole+amox+tetr+levo
Description: (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
Study: NCT02821689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
Study: NCT00996619

Intervention type: PROCEDURE
Intervention: An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination
Description: An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope
Study: NCT03055819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brow Lift
Description: Minimally Invasive Brow Lift
Study: NCT02577848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 were taken daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were taken daily for 7 days
Study: NCT00125619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor training
Description: This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
Study: NCT00803335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogen cream 0.5gm
Description: Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogen cream 1.0gm
Description: Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
Study: NCT02368691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
Study: NCT02977468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck 3475 Pembrolizumab
Description: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
Study: NCT03296007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
Study: NCT06330857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic vaginorectopexy
Description: Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
Study: NCT01641289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: \>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Paracetamol
Description: No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
Study: NCT02302625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
Study: NCT02543697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adrenal venous sampling
Description: We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
Study: NCT01372826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group1
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group 2
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group3
Description: Oral dose, 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118
Description: Oral dose, 25 mg
Study: NCT02924532

Intervention type: BIOLOGICAL
Intervention: immediate post operative bioassay of Parathyroid Hormone
Study: NCT02709798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose Injection
Study: NCT04950790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxinin injection
Description: Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
Study: NCT01838447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
Study: NCT02326740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab open-label
Study: NCT02924181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartTouch Catheter
Description: Pulmonary vein (PV) isolation guided by CF information

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartTouch Catheter
Description: Pulmonary vein (PV) isolation guided by CF information
Study: NCT02569970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine 20 mg
Description: Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 20 mg
Description: Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Study: NCT04589377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
Study: NCT04557215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC) is a clinically approved mucolytic agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
Study: NCT04293939

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Magnetic Risonance Imaging (fMRI) acquisition
Description: Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (\~15 cm area) with a soft brush at a velocity of \~5 cm/s Stimulus blocks will last for \~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (\~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Magnetic Risonance Imaging (fMRI) acquisition
Description: Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (\~15 cm area) with a soft brush at a velocity of \~5 cm/s Stimulus blocks will last for \~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (\~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
Study: NCT02464423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)
Study: NCT03028688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula oxygen
Description: Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
Study: NCT01598064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GK#10
Description: GK#10, 1 pack tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pack tid po
Study: NCT00005777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target (\>52 mm Hg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target (\>52 mm Hg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The infants in the placebo groups received equal volumes of saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The infants in the placebo groups received equal volumes of saline.
Study: NCT00628212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02527733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab and laser